Newborn Screening for Spinal Muscular Atrophy in the UK: Use of Modelling to Identify Priorities for Ongoing Evaluation
Open Access
- 13 January 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (1) , 3
Abstract
Spinal muscular atrophy (SMA) is a genetic condition that causes the degeneration of motor neurons in the spinal cord. Newborn blood spot (NBS) screening can potentially enable diagnosis before symptoms, and presymptomatic treatment is considered to be more effective than symptomatic treatment. In this paper, we present an overview of a cost-effectiveness model of NBS screening for SMA in the UK, informed by key clinical trials and the relevant published literature. Our analyses suggest that implementing screening could result in better outcomes and lower costs compared to the current approach of no screening plus treatment. However, several uncertainties and limitations of the model remain. These include uncertainty in the reimbursement status of nusinersen and risdiplam in the future; the ‘actual’ costs of treatments, as they are under confidential commercial agreements; uncertainty in the long-term effectiveness of presymptomatic and symptomatic treatment; and uncertainty around the incidence of SMA and the costs and the accuracy of NBS screening. An SMA in-service evaluation (ISE) that could capture data specific to the UK is under consideration, and an appropriately designed ISE with ongoing data collection could support periodic updates of clinical and cost-effectiveness estimates of NBS screening for SMA in the UK.Keywords
Funding Information
- UK National Screening Committee
This publication has 45 references indexed in Scilit:
- Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the USJAMA Pediatrics, 2024
- Clinical Effectiveness of Newborn Screening for Spinal Muscular AtrophyJAMA Pediatrics, 2024
- Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudyMuscle & Nerve, 2023
- Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in EnglandNeurology and Therapy, 2023
- Room to improve: The diagnostic journey of Spinal Muscular AtrophyEuropean Journal of Paediatric Neurology, 2022
- Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular AtrophyThe Journal of Pediatrics, 2020
- PMU30 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING FOR SPINAL MUSCULAR ATROPHY (SMA) IN THE UNITED STATESValue in Health, 2020
- An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical TrialsCNS Drugs, 2019
- Quality of life of patients with spinal muscular atrophy: A systematic reviewEuropean Journal of Paediatric Neurology, 2019
- Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2American Journal of Medical Genetics Part A, 2004